designed to be the "clean" one
1998 (published discovery paper); developed within Novo Nordisk's chemistry program in the mid-to-late 1990s
Ipamorelin's family tree began with a working drug for a lock nobody had found yet — in the late 1970s, a Tulane opioid researcher noticed his painkiller peptides were quietly dumping growth hormone into pituitary cells, two full decades before science identified the receptor they pulled on or ghrelin, the hormone that normally pulls it.
The story doesn't start with ipamorelin at all — it starts in a New Orleans lab in the late 1970s, where Tulane University endocrinologist Cyril Y. Bowers was tinkering with enkephalins, the body's own opioid-like painkiller peptides. Building small structural variants to probe how they worked, Bowers and his team stumbled onto analogs that had zero painkilling activity yet somehow made pituitary cells release growth hormone. It was textbook reverse pharmacology: they had a working key years before anyone found the lock — the receptor these peptides latched onto, later named GHS-R1a, wasn't identified until 1996, and its natural hormone, ghrelin, wasn't discovered until 1999. By 1984 Bowers had refined that unexpected family into GHRP-6, the first synthetic hexapeptide to reliably trigger GH release without routing through the usual GHRH pathway.
The trouble was that GHRP-6 was sloppy — it also nudged up cortisol, prolactin, and ACTH, hormones nobody wanted rising just to squeeze out more growth hormone. Solving that imprecision became a 1990s project at Novo Nordisk, where a team led by Kirsten Raun (internal code NNC 26-0161) ran a large structure-activity program built directly on Bowers' lineage. Their fix was almost architectural: they took the relative GHRP-1, surgically snipped out its central Ala-Trp dipeptide, and stabilized the shortened chain with an unusual amino acid, aminoisobutyric acid (Aib), at the front. The five-residue result — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — was ipamorelin.
The payoff landed in the European Journal of Endocrinology in November 1998, under the confident title 'Ipamorelin, the first selective growth hormone secretagogue.' In that study's pig pituitary cell cultures and animal models, ipamorelin released growth hormone with potency rivaling GHRP-6 — yet even at more than 200 times the effective GH-releasing dose, it produced no significant rise in ACTH or cortisol. For a drug family whose earlier members had essentially fired several neuroendocrine pathways at once just to get one result, that was a remarkable margin: the first GHRP-class compound to isolate the GH-release effect this precisely, a selectivity profile that until then only the body's own GHRH had shown.
The load-bearing science all checks out: Bowers' Tulane opioid work spinning off a growth-hormone-releasing peptide family, the receptor and ghrelin arriving two decades later, the 1998 Novo Nordisk paper, the GHRP-1-minus-Ala-Trp-plus-Aib recipe, and the 200x selectivity margin are traceable to primary sources. The embellishment lives only in the popular retelling — the crisp "1977" date and "happy accident" framing come mostly from peptide-vendor blogs, so we've kept it to the corroborated "late 1970s."
In 2026, ipamorelin sits at the heart of the compounded-peptide longevity boom, almost always sold as half of the "CJC-1295/Ipamorelin" stack that anti-aging and functional-medicine clinics pitch for sleep, recovery, and fat loss. Its legal footing, though, is genuinely unresolved: the FDA removed ipamorelin from its interim 503A compounding-bulks list in September 2024 after the original nominator withdrew, and in October 2024 the Pharmacy Compounding Advisory Committee voted against recommending it for the list. That leaves it uncleared for compounding rather than either approved or banned — with no FDA-approved medical indication, and sold almost entirely as a compounded or research-grade product.
